Jazz Pharmaceuticals plc or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Jazz Pharmaceuticals plc and Amneal Pharmaceuticals, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Jazz Pharmaceuticals consistently reported higher SG&A expenses, peaking at approximately 1.45 billion in 2021. This represents a staggering 257% increase from their 2014 figures. In contrast, Amneal Pharmaceuticals, while also experiencing growth, maintained a more modest increase of around 408% over the same period, reaching about 430 million in 2023.

This data suggests that while Jazz Pharmaceuticals has a larger scale of operations, Amneal Pharmaceuticals might be more efficient in managing their SG&A costs relative to their size. As the pharmaceutical industry continues to evolve, these insights could be pivotal for investors and stakeholders looking to understand cost management strategies.